Navigation Links
Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System

Presence at the EuroPCR08 will highlight choice of different modalities

available on single integrated imaging platform.

SAN DIEGO, and BRUSSELS, Belgium, May 12 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the 1,000th worldwide placement of the newest s5 and s5i integrated imaging consoles since the formal launch in April of 2006. This announcement comes just prior to Volcano's participation in the EuroPCR 2008 Congress, to be held in Barcelona, Spain, from May 12-15th. During the PCR, Volcano will highlight the s5i integrated Imaging System, complete with two new functionality options, which enable high frequency rotational IVUS and FFR to operate on the same platform as Volcano's phased array IVUS catheters.

Scott Huennekens, President and Chief Executive Officer of Volcano, commented, "Reaching this milestone as quickly as we have is a clear indication of the clinical adoption of IVUS and FFR, and the competitiveness of our product. More and more physicians are using intravascular imaging to measure lesion significance and improve PCI technique. The ease of use and flexibility of our newest systems have been very well received. These new systems are gaining traction with both new IVUS users, as well as those who are looking to replace their legacy IVUS technology."

The newest Volcano s5i integrated system now available for evaluation is the only imaging system that accommodates phased array IVUS, high frequency rotational IVUS, and integrated FFR lesion severity assessment. Mr. Huennekens continued, "By adding high resolution rotational IVUS and pressure-based FFR to our phased array s5 imaging platform, we provide a level of technology, clinical utility and convenience that is un-matched in the intravascular imaging field. No other company provides a system that integrates this level of functionality and convenience in a single platform. Our message now is simple: Volcano offers physicians all three technologies on one system -- you can choose which technology is best for your patient and clinical team."

Earlier generation consoles included only one of the three technologies now available on the s5i. If a hospital wanted to equip a new lab with all three technologies, they would have to acquire three separate consoles, each with a different measurement modality, training requirements and data storage protocols. The Volcano s5i can now accommodate three primary intravascular diagnostic tools in regular use by cardiologists today (high frequency rotational IVUS, fast and simple phased array IVUS, and pressure-based FFR guidewires) on a single platform, making Volcano's s5 and s5i imaging systems more flexible than ever before.

Presence at EuroPCR08

Volcano's presence at the EuroPCR 2008 Congress in Barcelona will include live case transmissions with IVUS, FFR, and OCT, scientific symposia sponsorship, first-in-man clinical experience and live product demonstrations at Volcano booth #B02. Volcano will also participate in the following scientific symposia during the program.

Title Date & Time Location

"Controversies in Coronary

Intravascular Imaging" May 14th, 12:00 - 13:30 Room 3

"Optimizing stent implantation and

minimizing irradiation for complex

PCI" with GE Healthcare May 15th, 16:30 - 18:30 Room 6

"IVUS Virtual Histology for Physicians"

-- Training Village with Cordis May 13th, 16:00 - 17:30 Room 131

"IVUS Virtual Histology for cath lab

nurses and technicians" -- Training

Village with Cordis May 15th, 14:00 - 15:30 Room 131

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options such as VH(TM) tissue characterization and ChromaFlo(R). Internal DICOM networking provided by DICOM by Merge. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra high-resolution Optical Coherence Tomography systems and catheters. Currently, more than 3,200 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's success and timing of product development and new product introductions, including the installations of the Volcano imaging systems, the expected performance of its products and product enhancements, the integration of our products into new or existing cath labs, and market penetration, conditions and expectations. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly report on Form 10-Q, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
2. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
3. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
4. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
5. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
6. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
7. Volcano Announces Closing of CardioSpectra Acquisition
8. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
9. Volcano Corporation Announces Pricing of Common Stock Offering
10. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
11. NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):